PATHFx - an intelligent decision support for better treatment of cancer patients with skeletal metastases
| Reference number | |
| Coordinator | Prognostix AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | November 2019 - April 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 autumn 2019 |
Important results from the project
Our AI-based prognostic decision support PATHFx is available free of charge to physicians globally (www.pathfx.org) as a support for the treatment of cancer patients with bone metastases. The greatest benefit is when PATHFx is integrated in the patient health record which avoids separate login and the computer itself retrieves the desired patient data. An integration project is underway at NKS with eligibility requirements that PATHFx has a CE license. In addition migration of the website from the USA to Sweden is required, where our patient data register is located.
Expected long term effects
Thanks to Vinnova´s contributing support, we have succeeded in our goal of qualifying for a CE license that lasts for 3 years. We have also successfully moved our website from the USA to Sweden and secured our trademark in important regions. We can now focus on commercialization and further development of our decision support.
Approach and implementation
Both the work with the CE license and the migration of the website have required coordination of actors in both the USA and Sweden. The CE work has been coordinated by a Swedish consulting company with the help of, among other methods, video meetings. The migration of the website has been handled by a Swedish IT company that takes over both the "back and front end" of the website